Kestra Medical Technologies (NASDAQ:KMTS) Price Target Raised to $32.00 at BTIG Research

Kestra Medical Technologies (NASDAQ:KMTS) had its price objective lifted by BTIG Research from $30.00 to $32.00 in a report released on Wednesday morning, Marketbeat Ratings reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also recently weighed in on the stock. The Goldman Sachs Group cut their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Wall Street Zen raised shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Weiss Ratings upgraded shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 30th. Finally, Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research note on Wednesday. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $27.83.

Kestra Medical Technologies Stock Up 1.8%

KMTS opened at $24.61 on Wednesday. Kestra Medical Technologies has a 12 month low of $13.25 and a 12 month high of $30.00. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. The stock has a market cap of $1.44 billion, a P/E ratio of -10.17 and a beta of 0.47. The stock’s 50 day moving average price is $22.17 and its 200 day moving average price is $22.73.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 60.60% and a negative net margin of 138.35%.The business had revenue of $28.64 million for the quarter. As a group, research analysts predict that Kestra Medical Technologies will post -2.16 earnings per share for the current year.

Insider Buying and Selling at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $20.81, for a total value of $312,150.00. Following the completion of the sale, the insider owned 395,467 shares in the company, valued at $8,229,668.27. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 3.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kestra Medical Technologies

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its stake in shares of Kestra Medical Technologies by 137.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after purchasing an additional 2,529,851 shares during the last quarter. Franklin Resources Inc. lifted its stake in Kestra Medical Technologies by 180.8% during the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after purchasing an additional 612,343 shares during the last quarter. Millennium Management LLC acquired a new stake in Kestra Medical Technologies during the first quarter valued at approximately $11,036,000. Brown Advisory Inc. boosted its holdings in Kestra Medical Technologies by 34.1% during the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after buying an additional 428,996 shares in the last quarter. Finally, Summit Partners Public Asset Management LLC acquired a new position in Kestra Medical Technologies in the fourth quarter worth approximately $9,282,000.

Key Stories Impacting Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: BTIG Research raised its price target on Kestra Medical Technologies to $32 from $30 and reiterated a Buy rating, signaling confidence in roughly 30% upside from the current share price. BTIG Raises Price Target on Kestra Medical Technologies
• Positive Sentiment: The company secured a $200 million non-dilutive financing facility, which should strengthen liquidity and help fund growth without immediately diluting shareholders. Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing
• Positive Sentiment: Management issued FY2027 revenue guidance of about $137 million, slightly above Wall Street expectations, suggesting continued top-line growth momentum. Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results
• Neutral Sentiment: The company reported fourth-quarter revenue of $28.64 million, which topped expectations, but the earnings call transcript and release largely reiterated the quarter’s operating details. Kestra Medical Technologies Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Kestra posted a quarterly loss of $0.67 per share, wider than the expected loss of $0.59, highlighting that profitability remains a challenge despite better-than-expected revenue. Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.